HI
CSTL icon

Harbour Investments’s Castle Biosciences CSTL Stock Holding History

Harbour Investments’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$94.9K Buy
3,977
+729
+22% +$16.2K ﹤0.01% 2031
2026
Q1 		$79.7K Buy
3,248
+111
+4% +$3.64K ﹤0.01% 2076
2025
Q4 		$122K Hold
3,137
– – ﹤0.01% 1535
2025
Q3 		$71.4K Buy
3,137
+150
+5% +$3.05K ﹤0.01% 1724
2025
Q2 		$61K Buy
2,987
+487
+19% +$9.02K ﹤0.01% 1716
2025
Q1 		$50K Buy
+2,500
New +$61.9K ﹤0.01% 1762
2024
Q3 		– Sell
-2,270
Closed -$49.4K – 3416
2024
Q2 		$49.4K Buy
+2,270
New +$50.6K ﹤0.01% 1554
2021
Q4 		– Sell
-950
Closed -$63K – 2842
2021
Q3 		$63K Hold
950
– – ﹤0.01% 1628
2021
Q2 		$70K Hold
950
– – ﹤0.01% 1601
2021
Q1 		$65K Buy
+950
New +$71.4K ﹤0.01% 1518

Other funds holding CSTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Harbour Investments's CSTL Position: Q2 2026 in Review

Harbour Investments increased its Castle Biosciences (CSTL) stake by 22% in Q2 2026, buying an estimated $16.2K and bringing the position to 3,977 shares worth $94.9K. The position accounts for ﹤0.01% of the portfolio, ranked #2031.

Harbour Investments first reported a position in CSTL in Q1 2021 and has held it in 10 quarters since. The position peaked at $122K in Q4 2025. 177 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

  • Harbour Investments held 3,977 shares of Castle Biosciences worth $94.9K as of Q2 2026.
  • Harbour Investments bought 729 Castle Biosciences shares in Q2 2026, an estimated $16.2K.
  • Castle Biosciences made up ﹤0.01% of Harbour Investments's portfolio in Q2 2026, its #2031 holding.
  • Harbour Investments first reported a position in Castle Biosciences in Q1 2021 and has held it in 10 quarters since.
  • Harbour Investments's Castle Biosciences position peaked at $122K in Q4 2025.
  • 177 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on Harbour Investments's 13F filing for Q2 2026, filed 12 Aug 2026.